Piotr Leszczyński

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

Gerd R Burmester, Andrea Rubbert‐Roth, Alain Cantagrel et al. · Annals of the Rheumatic Diseases · 2013 · 237 citations · Full text

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Annals of the Rheumatic Diseases · 2015 · 226 citations · Full text

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

Megan E. B. Clowse, Daniel J. Wallace, Richard Furie et al. · Arthritis & Rheumatology · 2016 · 223 citations · Full text

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

Gerd R Burmester, Andrea Rubbert‐Roth, Alain Cantagrel et al. · Annals of the Rheumatic Diseases · 2015 · 122 citations · Full text

Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4

Paul Emery, Jiří Vencovský, Anna Sylwestrzak et al. · Annals of the Rheumatic Diseases · 2017 · 109 citations · Full text